Literature DB >> 21062009

Design, synthesis, and structure-activity relationships of 3-ethynyl-1H-indazoles as inhibitors of the phosphatidylinositol 3-kinase signaling pathway.

Elisa Barile1, Surya K De, Coby B Carlson, Vida Chen, Christine Knutzen, Megan Riel-Mehan, Li Yang, Russell Dahl, Gary Chiang, Maurizio Pellecchia.   

Abstract

A new series of 3-ethynyl-1H-indazoles has been synthesized and evaluated in both biochemical and cell-based assays as potential kinase inhibitors. Interestingly, a selected group of compounds identified from this series exhibited low micromolar inhibition against critical components of the PI3K pathway, targeting PI3K, PDK1, and mTOR kinases. A combination of computational modeling and structure-activity relationship studies reveals a possible novel mode for PI3K inhibition, resulting in a PI3Kα isoform-specific compound. Hence, by targeting the most oncogenic mutant isoform of PI3K, the compound displays antiproliferative activity both in monolayer human cancer cell cultures and in three-dimensional tumor models. Because of its favorable physicochemical, in vitro ADME and drug-like properties, we propose that this novel ATP mimetic scaffold could prove useful in deriving novel selecting and multikinase inhibitors for clinical use.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21062009      PMCID: PMC3131451          DOI: 10.1021/jm100825h

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  38 in total

1.  Ligand efficiency: a useful metric for lead selection.

Authors:  Andrew L Hopkins; Colin R Groom; Alexander Alex
Journal:  Drug Discov Today       Date:  2004-05-15       Impact factor: 7.851

2.  High frequency of mutations of the PIK3CA gene in human cancers.

Authors:  Yardena Samuels; Zhenghe Wang; Alberto Bardelli; Natalie Silliman; Janine Ptak; Steve Szabo; Hai Yan; Adi Gazdar; Steven M Powell; Gregory J Riggins; James K V Willson; Sanford Markowitz; Kenneth W Kinzler; Bert Vogelstein; Victor E Velculescu
Journal:  Science       Date:  2004-03-11       Impact factor: 47.728

3.  Ligand efficiency indices as guideposts for drug discovery.

Authors:  Cele Abad-Zapatero; James T Metz
Journal:  Drug Discov Today       Date:  2005-04-01       Impact factor: 7.851

Review 4.  Capturing complex 3D tissue physiology in vitro.

Authors:  Linda G Griffith; Melody A Swartz
Journal:  Nat Rev Mol Cell Biol       Date:  2006-03       Impact factor: 94.444

5.  Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes.

Authors:  M D Eldridge; C W Murray; T R Auton; G V Paolini; R P Mee
Journal:  J Comput Aided Mol Des       Date:  1997-09       Impact factor: 3.686

6.  Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery.

Authors:  S R Datta; H Dudek; X Tao; S Masters; H Fu; Y Gotoh; M E Greenberg
Journal:  Cell       Date:  1997-10-17       Impact factor: 41.582

7.  Development and validation of a genetic algorithm for flexible docking.

Authors:  G Jones; P Willett; R C Glen; A R Leach; R Taylor
Journal:  J Mol Biol       Date:  1997-04-04       Impact factor: 5.469

8.  Texture mapping: a new tool for molecular graphics.

Authors:  M Teschner; C Henn; H Vollhardt; S Reiling; J Brickmann
Journal:  J Mol Graph       Date:  1994-06

Review 9.  Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis.

Authors:  Megan Cully; Han You; Arnold J Levine; Tak W Mak
Journal:  Nat Rev Cancer       Date:  2006-03       Impact factor: 60.716

10.  Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling.

Authors:  Nathan T Ihle; Ryan Williams; Sherry Chow; Wade Chew; Margareta I Berggren; Gillian Paine-Murrieta; Daniel J Minion; Robert J Halter; Peter Wipf; Robert Abraham; Lynn Kirkpatrick; Garth Powis
Journal:  Mol Cancer Ther       Date:  2004-07       Impact factor: 6.261

View more
  2 in total

Review 1.  Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents.

Authors:  Yu Liu; Wen-Zhu Wan; Yan Li; Guan-Lian Zhou; Xin-Guang Liu
Journal:  Oncotarget       Date:  2017-01-24

Review 2.  Multitargeting the Action of 5-HT6 Serotonin Receptor Ligands by Additional Modulation of Kinases in the Search for a New Therapy for Alzheimer's Disease: Can It Work from a Molecular Point of View?

Authors:  Kinga Czarnota-Łydka; Katarzyna Kucwaj-Brysz; Patryk Pyka; Wawrzyniec Haberek; Sabina Podlewska; Jadwiga Handzlik
Journal:  Int J Mol Sci       Date:  2022-08-07       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.